8:00 am Chair’s Opening Remarks

8:15 am Key Features of Neoepitope Predictions

  • Fred Ramsdell VP of Research, Parker Institute for Cancer Immunotherapy


  • Analysis of multiple neoepitope computational pipelines defines specific features associated with T cell responses
  • T cell assay sensitivity influences the level of response
  • Integration of the computational results suggest areas for technological focus to improve predictions

8:45 am Using Normal Immune Responses as the Engine for Cancer Immunotherapy


• Antigen selection – define the power of neoantigens
• Antigen delivery – setting immunologic goals and choosing the right vectors for humans
• Are we meeting the goal(s) and seeing clinical efficacy?

9:15 am ImmunoID NeXT: A Comprehensive Platform for Improving Neoantigen Prediction, Tumor Escape Mechanism Reporting, TME Assessment, and Tumor Heterogeneity Profiling for Immuno-Oncology

  • Sean Boyle Senior Director, Bioinformatics Applications, Personalis Inc


• Improving neoantigen presentation prediction – Applying immunopeptidomics and machine learning to more accurately predict neoantigens
• Detecting tumor escape mechanisms – HLA LOH, antigen presentation machinery, and immunogenomics
• Profiling tumor heterogeneity – Utilizing cell free DNA in order to more comprehensively identify neoantigens and tumor escape mechanisms

9:45 am Morning Refreshments & Speed Networking

Prediction & Discovery

Clinical & Translational

Assessing Conventional Neoantigen
Prediction Methods

Evaluating the Advantages and
Disadvantages of Delivery Platforms

10.45 Neoantigen Prediction: Approach and Validation

• Neoantigen identification for cancer immunotherapy remains a significant challenge
• Tumor immunopeptidomics combined with deep learning provides a powerful approach for neoantigen prediction
• Gritstone’s EDGETM prediction model identifies therapeutically relevant neoantigens

James Sun, Senior Director & Head of Bioinformatics, Gritstone Oncology

10.45 Update on Vaccibody’s Clinical Study Showing Vaccine-induced Clinical Responses in Multiple Patients with Advanced or Metastatic Disease

• Inducing a unique CD8-dominated T cell response by targeting antigens to APC
• Discuss the link between immune responses, the optimal choice of neopitopes and anti-tumour efficacy
• Share clinical updates on the phase I/IIa VB N-01 trial in multiple indications

Agnete Fredriksen, CSO, Vaccibody

11.15 Neoantigen-specific T cell Responses: Learnings
from Preclinical Studies with the RNA-LPX Vaccine

• Evaluate rules defining immunogenic neoepitopes
• Define mechanistic drivers of efficacy following vaccination

Lelia Delamarre, Senior Scientist, Cancer Immunology
Research, Genentech

11.15 Harnessing Oncolytic Viruses for Personalized
Neoantigen Immunotherapy

• Describe our novel T cell vaccine approach using engineered replicating viruses targeting personalized neoantigens
• Review our design approach to tackle several bottlenecks of current vaccine technologies regarding magnitude, breadth and persistence of CD8 T cell responses against multiple neoantigen targets
• Additionally, our virus based boosting strategy is uniquely modular and flexible for rapid clinical deployment

David Stojdl, SVP of Discovery Research, Turnstone Biologics

11.45 Connecting Neoantigens to TCR Recognition

• Evaluate how not all aberrations are equal in the eye of the immune system, only some non-self-aberrations are processed and presented
• Discuss how some presented peptides are recognised and impart effective immune response
• Outline how TCRs have a defined specificity for recognition
• Only some non-self-aberrations are processed and presented
• Only some presented peptides are recognised and impart effective immune response
• TCRs have a defined specificity for recognition

John Castle, Head of Translational Medicine & Bioinformatics, Agenus

11.45 mRNA Vaccines – A New Modality to Target Cancer Neoantigens

• mRNA based vaccines- design, mode of action and delivery
• Outline preclinical and clinical development
• Review regulatory considerations

Ulrike Gnad-Vogt, CMO & Head of Clinical Development, Curevac

12.15 Identification of Novel Shared Targets in Solid Tumors

• Yeast display technology to define peptide MHC complexes binding to a lead TCR
• Defining all peptide MHC complexes that bind to a given T- cell receptor
• Peptide MHC profiling of clinical TCRs to improve safety while maintaining activity

Hanspeter Gerber, SVP & CSO, 3T Biosciences

12.15 A Pyroptosis-inducing DNA Vaccine Adjuvant Amplifies Tumour-specific T Cell Responses and Tumour Control

• Pyroptosis is a form of inflammatory cell death involving caspase-1 activation
• Outline our design for a constitutively active form of caspase-1
• DNA coding for active caspase-1 improves the immunogenicity of neoantigen DNA vaccines

Jeroen van Bergen, Director of Research, Immunetune

12:45 pm Lunchtime Refreshments & Networking

Standardizing Neoantigen Discovery Processes
to Uncover Best Validation Methods

Delivery Platforms to Maximise Immunogenicity

13.45 Sources of Variability in Neoantigen Prediction

• Status update on neoantigen trials at Mount Sinai
• Description of the genomics/neoantigen prediction pipeline used for those trials
• Qualitative and quantitative comparison of several neoantigen prediction tools

Julia Kodysh, Computational Researcher, Icahn School of Medicine at Mount Sinai

13.45 NousCom Neoantigen-based Cancer Vaccine for potent, broad and effective anti-tumor T cell immunity

• Define how neoantigen vaccines based on Adenoviruses derived from non-human Great Apes (GAd) elicit strong immune response and are highly effective as stand-alone treatment, however treatment of large tumors requires combination of GAd with checkpoint inhibitors (CPI)
• Review how the effectiveness of vaccination is CD8 mediated and correlates with the breadth and potency of T cell responses induced by vaccination, including the expansion of the intratumoral T cell repertoire

Anna Morena D’Alise, Immunology Lead, Nouscom

14.15 Antigens that Matter - Highly Personalized Immunotherapy Approaches Applying the XPRESIDENT® Technology

• Review immatics XPRESIDENT® target discovery technology in the context of personalization
• Discuss neoantigens and unmutated antigens – chances and challenges
• Outline the highly personalized Adoptive Cellular Therapy
• GAPVAC approach: concept of actively personalized vaccination in newly diagnosed glioblastoma

Norbert Hilf, VP of Translational Development, Immatics

14.15 Using Combination of Viral Vectors to Maximize Efficacy of Cancer Vaccines

• Outline the use of viruses to prime against neoantigen sequences
• Review the effect of viruses on the adaptive response against the tumor
• Discuss the combination of various viral modalities to address lead time issues and maximize potency

Kaidre Bendjama, Project Leader, Personalized Cancer Vaccines & Clinical Biomarkers, Transgene

2:45 pm Afternoon Break & Poster Session

3:45 pm Neoantigen-Based Cancer Therapies: A Regulatory Perspective

  • Lydia Martynec Medical Officer, Officer of Tissues and Advanced Therapies, FDA


  • Review the current landscape
  • Outline common regulatory challenges
  • Share guidance on clinical trial design

4:15 pm An Integrated Machine-Learning Approach to Improve the Prediction of Clinically Relevant Neoantigens


• Outline a high-performing machine learning approach, trained on mass spectrometry data, that predicts naturally processed and presented antigens
• Demonstrate how the predictor is integrated with several immune parameters, such HLA binding, in a deep learning layer to predict bona fide neoantigens
• Illustrate it’s application to significantly improve the identification of neoantigen targets for personalized cancer immunotherapy

4:45 pm Shouldn’t Each Patient’s Immune System Define True Personalized Neoantigens?


ATLAS™, an autologous immune assay that identifies specific immunogenic neoantigens, is more effective at identifying true neoantigens for both CD4 AND CD8 targets than algorithms predictions focused on MHC presentation, and also identifies immunosuppressive peptides

• GEN-009, a neoantigen vaccine, is feasible and safe for patients
• Share clinical data from resected cancer patients show broad and robust immune responses against the vast majority of vaccine antigens selected by ATLAS

5:15 pm Highly Efficient Neoantigen Production Incorporating a New Green Solvent

  • Jon Collins Vice President of Business Development , CEM Corporation


• Integration of new green solvent to replace the traditional and more toxic dimethylformamide (DMF) and N-methyl-2-pyrrolidone (NMP).
• Utilization of microwave energy and newly developed, one-pot Fmoc solid phase peptide synthesis (SPPS) process for production of neoantigen peptides.
• Highly efficient and safer process meets the needs of rapid and low cost neoantigen production

5:25 pm Neoantigen Therapeutics Come of Age


• Discuss experience utilizing a personal neoantigen vaccine in combination with a checkpoint inhibitor and, in certain cases, chemotherapy, to treat patients with high mutational burden tumors in the metastatic setting
• Outline Neon’s personalized T cell approach, investigating ex vivo immunization of multiple T cell populations that are generated to target each individual patient’s unique set of neoantigens
• Strategies to identify neoantigens that are conserved in specific tumors across a broader spectrum of patients which can be adapted for treatment through either vaccine or T cell based therapies

5:55 pm Chair’s Closing Remarks

6:00 pm NeoAg Summit Drinks Reception hosted by PolyPeptide